In a report issued on August 13, David Novak from Raymond James maintained a Buy rating on Zymeworks Inc (NYSE: ZYME), with a price target of $27. The company’s shares closed yesterday at $14.17.
According to TipRanks.com, Novak is ranked #3765 out of 4857 analysts.
Currently, the analyst consensus on Zymeworks Inc is a Strong Buy with an average price target of $26.25, an 85.3% upside from current levels. In a report issued on August 2, Citigroup also upgraded the stock to Buy with a $20 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $29 and a one-year low of $6.76. Currently, Zymeworks Inc has an average volume of 197.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that can two non-overlapping epitopes.
